Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Net Income (2021 - 2025)

Historic Net Income for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $51.4 million.

  • Krystal Biotech's Net Income rose 1291.5% to $51.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $204.8 million, marking a year-over-year increase of 12962.93%. This contributed to the annual value of $204.8 million for FY2025, which is 12973.68% up from last year.
  • As of Q4 2025, Krystal Biotech's Net Income stood at $51.4 million, which was up 1291.5% from $79.4 million recorded in Q3 2025.
  • Krystal Biotech's Net Income's 5-year high stood at $80.7 million during Q3 2023, with a 5-year trough of -$50.0 million in Q1 2022.
  • Moreover, its 5-year median value for Net Income was -$7.3 million (2021), whereas its average is $4.8 million.
  • In the last 5 years, Krystal Biotech's Net Income crashed by 21599.42% in 2022 and then surged by 373015.02% in 2025.
  • Krystal Biotech's Net Income (Quarter) stood at -$21.8 million in 2021, then crashed by 46.99% to -$32.1 million in 2022, then skyrocketed by 127.12% to $8.7 million in 2023, then surged by 423.62% to $45.5 million in 2024, then increased by 12.91% to $51.4 million in 2025.
  • Its Net Income stands at $51.4 million for Q4 2025, versus $79.4 million for Q3 2025 and $38.3 million for Q2 2025.